New drug FS1502 targets Hard-to-Treat HER2 cancers in early trial
NCT ID NCT03944499
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called FS1502 in 161 people with advanced solid tumors or breast cancer that express HER2. The study had two parts: first, finding a safe dose, and then seeing how well that dose works. The goal was to check safety and early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FS-1502 (an experimental drug given by IV)
What this could lead to
If it works, this could point toward a new treatment option for people with HER2-positive advanced solid tumors or breast cancer.
What could go wrong
This is a very early Phase 1 trial with only 161 participants, so safety and dosing are still being figured out. It may not show strong anti-tumor effects or lead to a widely available therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Jilin Cancer Hospital
Jilin City, Changchun, China
-
Meizhou People's Hospital
Meizhou, Guangdong, China
-
Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University
Hangzhou, Zhejiang, 310016, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
Shenzhen, Guangdong, 518000, China
-
Sun Yat-sen University Cancer Prevention Center
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China